An experimental compound inhibited clot formation without increased bleeding, a common side effect of current anticlotting therapies, in a phase I study. First-in-human study shows the anticlotting drug was well-tolerated without serious safety concerns in healthy volunteers. Next-phases will gauge effectiveness and safety in patients with acute ischemic strokes.
Source: Care Giving Science Daily